Olanzapine Mylan

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
14-07-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
14-07-2023

Viambatanisho vya kazi:

olanzapine

Inapatikana kutoka:

Mylan Pharmaceuticals Limited

ATC kanuni:

N05AH03

INN (Jina la Kimataifa):

olanzapine

Kundi la matibabu:

Psycholeptics

Eneo la matibabu:

Schizophrenia; Bipolar Disorder

Matibabu dalili:

AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Bidhaa muhtasari:

Revision: 19

Idhini hali ya:

Authorised

Idhini ya tarehe:

2008-10-06

Taarifa za kipeperushi

                                84
B. PACKAGE LEAFLET
85
PACKAGE LEAFLET: INFORMATION FOR THE USER
OLANZAPINE MYLAN 2.5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 7.5 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 10 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 15 MG FILM-COATED TABLETS
OLANZAPINE MYLAN 20 MG FILM-COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Olanzapine Mylan is and what it is used for
2.
What you need to know before you take Olanzapine Mylan
3.
How to take Olanzapine Mylan
4.
Possible side effects
5.
How to store Olanzapine Mylan
6.
Contents of the pack and other information
_ _
1.
WHAT OLANZAPINE MYLAN IS AND WHAT IT IS USED FOR
Olanzapine Mylan contains the active substance olanzapine. Olanzapine
belongs to a group of
medicines called antipsychotics and is used to treat the following
conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
Olanzapine Mylan has been shown to prevent recurrence of these
symptoms in patients with bipolar
disorder whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE OLANZAPINE MYLAN
DO NOT TAKE OLANZAPINE MYLAN
•
if you are allergic (hypersensitive) to olanzapine, peanut or soya or
any 
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Olanzapine Mylan 2.5 mg film-coated tablets
Olanzapine Mylan 5 mg film-coated tablets
Olanzapine Mylan 7.5 mg film-coated tablets
Olanzapine Mylan 10 mg film-coated tablets
Olanzapine Mylan 15 mg film-coated tablets
Olanzapine Mylan 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Olanzapine Mylan 2.5 mg film-coated tablets
Each film-coated tablet contains 2.5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 76 mg lactose (as monohydrate).
The film-coating of each 2.5 mg tablet contains 0.06 mg soya lecithin.
Olanzapine Mylan 5 mg film-coated tablets
Each film-coated tablet contains 5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 152 mg lactose (as monohydrate).
The film-coating of each 5 mg tablet contains 0.12 mg soya lecithin.
Olanzapine Mylan 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 228 mg lactose (as monohydrate).
The film-coating of each 7.5 mg tablet contains 0.18 mg soya lecithin.
Olanzapine Mylan 10 mg film-coated tablets
Each film-coated tablet contains 10 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 304 mg lactose (as monohydrate).
The film-coating of each 10 mg tablet contains 0.24 mg soya lecithin.
Olanzapine Mylan 15 mg film-coated tablets
Each film-coated tablet contains 15 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 183 mg lactose (as monohydrate).
The film-coating of each 15 mg tablet contains 0.15 mg soya lecithin.
Olanzapine Mylan 20 mg film-coated tablets
Each film-coated tablet contains 20 mg olanzapine.
Excipients with known effect
Each film-coated tablet contains 244 mg lactose (as monohydrate).
The film-coating of each 20 mg tablet contains 0.20 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Olanzap
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kireno 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 14-07-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 16-10-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 14-07-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 14-07-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 14-07-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 14-07-2023

Tafuta arifu zinazohusiana na bidhaa hii